Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Alidornase alfa: Interim Ph II data

February 10, 2017 9:21 PM UTC

Interim data from an open-label, Israeli Phase II trial in 13 evaluable CF patients previously treated with Pulmozyme dornase alfa showed that once-daily 2.5 mg inhaled alidornase alfa for 28 days led...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Protalix Biotherapeutics Inc.

BCIQ Target Profiles

Deoxyribonuclease I (DNASE1)